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Aim: The incidence and mortality associated with intrahepatic cholangiocarcinoma is increasing in many countries
and documentation of disease outcome is sparse. The present study was undertaken to investigate the prognostic
factors for intrahepatic cholangiocarcinoma (ICC) following surgical resection. The impact of pre-existing HBV virus
infection and adjuvant chemotherapy on the overall survival was also evaluated.
Methods: Clinical and pathological data were collected retrospectively from 81 patients undergoing surgery for ICC
between 2005 and 2011, at The Henan Province Tumor Hospital and the First Affiliated Hospital of Zheng Zhou
University. Survival and prognosis were analyzed using the Kaplan-Meier method and COX regression model.
Results: The population included 37 patients who were HBsAg + or anti-HBc+, 21 patients who were anti-HBs +
positive and 18 patients who received adjuvant chemotherapy. The overall 1- and 3-year survival rates were 51%
and 20%, respectively. The median survival was 12.2 months. Univariate analysis identified the following prognostic
factors: HBV virus infection or HBV vaccine prior to resection (P = 0.017); adjuvant chemotherapy (P = 0.001);
preoperative serum CA19-9 (> 200 U/mL; P = 0.015); GGT (> 64 U/L; P = 0.008), ALP (> 119 U/L; P = 0.01); lymph node
metastasis (P = 0.005); radical resection (P = 0.021); intrahepatic metastasis (P = 0.015) and diabetes (P = 0.07).
Multivariate analysis identified chronic HBV infection (RR = 0.583; P = 0.041), anti-HBs positivity (RR = 0.680; P = 0.050),
adjuvant chemotherapy (RR = 0.227; P < 0.001), lymph node metastasis (RR = 2.320; P = 0.001), and intrahepatic duct
stones (RR = 0.473; P = 0.032) as independent prognostic factors.
Conclusions: HBV virus infection or HBV vaccination prior to resection, together with adjuvant chemotherapy, were
independently associated with improved survival in patients undergoing surgery for ICC.
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Intrahepatic cholangiocarcinoma (ICC) is the second most
common form of primary hepatic tumor accounting for
3.3% of all such cancers. It originates from epithelial cells
located in the intrahepatic bile duct or at the end of the
bile duct. The incidence and mortality associated with
ICC are increasing in many countries [1]. Due to the lack
of typical symptoms that define early stage disease, many* Correspondence: lixingyavip@163.com
1First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Full list of author information is available at the end of the article
© 2013 Liu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orpatients present with lymph node metastasis at the time
of diagnosis. These patients are not suitable candidates for
hepatic resection which is the only therapy associated with
prolonged survival [2]. Consequently prognosis is gener-
ally poor.
Recent studies have identified HBV infection as an in-
dependent risk factor for ICC [3,4]. However the impact
of HBV infection on the outcome ICC remains unclear
[5,6]. In the present study we investigated the impact of
HBV infection on the survival of patients undergoing sur-
gical resection for ICC. Generally speaking, anti-hepatitis B
core (HBc)-positivity alone is either indicative of previousThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Overall survival rates after the surgical resection in 81 ICC
patients, 3 groups according to the 5 markers of HBV in serum.
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antigen (HBsAg). Anti-HBs, therefore, provides evidence of
recent infection, and acts as a sentinel marker for HBV in-
fection (HBsAg carrier). Occult HBV infection is some-
times identified by molecular techniques even in patients
who show HBsAg seronegativity [7,8]. However, previous
hepatitis B vaccination does not result in anti-HBc, because
the components of hepatitis B vaccine do not relate to
hepatitis B core antigen (HBcAg). Thus, the consensus is
that anti-HBc + alone indicates current or previous HBV
infection, while anti-HBs positivity is indicative of previous
infection or injection of HBV vaccine.
Much controversy surrounds the use of adjuvant chemo-
therapy for ICC. Most data come from small, uncontrolled
trials that include cases of gallbladder, pancreatic and biliary
system carcinoma [9], making it difficult to draw meaning-
ful conclusions regarding efficacy. In addition, there is no
consensus about standard chemotherapy.
Materials and methods
Patients
Clinical and pathological data were retrospectively col-
lected from 81 patients who underwent surgical resec-
tion of pathologically confirmed ICC between January
2005 and December 2011 at the Henan Province Tumor
Hospital and the First Affiliated Hospital of Zheng Zhou
University. Patients who had received pre-operative chemo-
therapy and those with hilar choangiocarcinoma or HCV
infection were excluded from the analysis.
The population included 48 men and 33 women, with a
median age of 59 years (range: 30 to 76 years). Fourteen
patients (17.2%) were heavy drinkers, 27 patients (33.3%)
were smokers and six (7.4%) had diabetes.
In total, 37 patients (45.7%) were anti-HBc + or HBsAg+,
21 (25.9%) were anti-HBs + and 23 patients (28.4%) were
negative for all five makers. Among the 37 anti-HBc + pa-
tients eight were also Anti-HBs positive. A significant pro-
portion of patients presented with abnormal preoperative
levels of liver function markers. Thirty six (44.4%) patients
had elevated ALT; AST was elevated in 37 patients (45.7%),
alkaline phosphatase in 51 patients (63.0%), GGT in 58 pa-
tients (71.6%), total bilirubin in 29 patients (35.8%) and al-
bumin in 23 patients (28.4%). In terms of tumor markers,
57 patients (70%) had CA19-9 levels above 37 U/mL, 47
(54.3%) had CA19-9 levels above 200 U/mL and eight pa-
tients (6.7%) had elevated alpha fetoprotein levels.
Imaging studies and surgical records showed that 50
patients (61.7%) had regional lymph node metastases;
31 (38.3%) had intrahepatic metastases, and 13 (16.0%)
had intrahepatic duct stones. Eighteen patients received
adjuvant chemotherapy after surgery. Twelve 12 pa-
tients received the transhepatic arterial chemotherapy
and embolization (TACE), and six received intravenous
chemotherapy.Statistical analysis
All the patients were followed up by the telephone or
mail until death or the study cut-off (20 October 2012).
Statistical analysis was performed using the SPSS ver-
sion 17.0 software. Overall survival time was calculated
from the date of surgery using the Kaplan-Meier method.
Survival rates between groups were compared using log-
rank and multivariate regression analysis. The Cox pro-
portional hazards model was used to identify independent




Patient survival ranged from 1 to 62 months (median:
12.2 months) with five patients still alive at the end of
the follow-up period. The overall 1- and 3-year survival
rates were 51% and 20%, respectively. The median sur-
vival time was 12.2 months.
The impact of HBV infection and vaccine on
postoperative outcome
The population was divided into three groups according
to the serum HBV markers. The first group who were
HBs-Ag or anti-HBc positive, represented patients with
previous or current infection; the second group who were
anti-HBs positive only, represented those with HBV infec-
tion or previous vaccination and the third group comprised
patients with negative serum markers of HBV, who had
never been infected with HBV. As shown in Figure 1 and
Table 1, median survival was longer in patients who were
Table 1 Univariate analysis of overall survival following
resection for ICC (n = 81)






Male 48 39.6% 9.2% 10
Female 33 48.5% 13.9% 12
Age 0.108
≤ 60 years 43 48.8% 15.2% 12
> 60 years 38 36.8% 6.3% 7
Intrahepatic duct stones 0.277
Yes 13 53.8% 15.4% 26
No 68 41.5% 10.7% 10
Serum hepatitis index 0.017
HBsAg or anti-HBc 37 45.9% 15.0% 12
anti-HBs + 21 52.4% 16.3% 13
All - 23 30.4% 0% 6
ALT 0.068
≤ 40 U/L 45 53.3% 13.2% 13
> 40 U/L 36 31.6% 9.8% 10
CA19-9 0.015
≤ 200 U/ml 34 50.0% 19.1% 12
> 200 U/ml 47 38.3% 5.1% 8
GGT 0.008
≤ 64 U/L 23 60.9% 19.1% 16
> 64 U/L 58 36.2% 7.9% 9
Total bilirubin 0.124
≤ 20 μmol/L 52 48.0% 13.6% 12
> 20 μmol/L 29 34.5% 6.9% 9
Alkaline phosphatase 0.01
≤ 119 U/L 30 60.0% 16.2% 15
> 119 U/L 51 33.3% 7.8% 8
Lymphatic metastasis 0.005
Yes 50 34.0% 6.0% 6
No 31 58.1% 20.2% 15
Operative procedure 0.021
Radical 60 45.0% 14.2% 12
Palliative 21 28.6% 0 5
Intrahepatic metastasis 0.015
Yes 31 29.0% 6.5% 6
No 50 52.0% 13.9% 13
Diabetes 0.07
Yes 6 16.7% 0 5
No 75 45.3% 12.0% 12
Table 1 Univariate analysis of overall survival following
resection for ICC (n = 81) (Continued)
Adjuvant chemotherapy 0.001
Yes 18 83.8% 33.3% 22
No 63 31.7% 4.1% 8
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in those with negative markers (6 months; P = 0.017). Sur-
vival among the eight HBsAb positive patients was similar
to that among HBs-Ag or anti-HBc positive patients.
The impact of adjuvant chemotherapy on the
ICC patients
Eighteen patients received adjuvant chemotherapy (Table 1)
including 12 patients who underwent transcatheter hepatic
arterial chemoembolization (TACE) and six patients who
received systemic venous antineoplastic therapy. Chemo-
therapy included 5-FU, cisplatin, gemcitabine, doxorubicine
and oxaliplatin. As shown in Figure 2, median survival
was significantly longer among patients receiving adju-
vant chemotherapy (22 months) than among those not
receiving chemotherapy (8 months; P = 0.01).
Effect of prognostic factors on survival
Univariate analysis (Table 1) indicated that preoperative
serum levels of CA19-9 (≥ 200 U/L), GGT (≥ 64U/L) and
ALP (≥ 119 U/L) were associated with improved survival
(Figures 3, 4 and 5). Other factors linked to survival benefit
were lymph node metastasis, radical surgery, intrahepatic
metastasis and diabetes (Figures 6, 7, 8 and 9).Figure 2 Overall survival rate in 81 ICC patients according to
received adjuvant chemotherapy or not.
Figure 3 Overall survival rate of in 81 ICC patients after surgery
according to the serum level of CA19-9 from the
Kaplan-Meier method.
Figure 5 Overall survival rate of in 81 ICC patients after surgery
according to the serum level of ALP from the
Kaplan-Meier method.
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infection (RR = 0.583; P = 0.041), anti-HBs positivity (RR =
0.680; P = 0.050), adjuvant chemotherapy (RR = 0.227; P <
0.001) and intrahepatic duct stones (RR = 0.473; P = 0.032)
as favorable independent prognostic factors while the pres-
ence of lymph node metastases was associated with poor
overall survival (RR = 2.320; P = 0.001).Figure 4 Overall survival rate of in 81 ICC patients after surgery
according to the serum level of GGT from the
Kaplan-Meier method.Stratification of prognostic factors by HBV status
Based on the preceding results we analyzed differences
in the distribution of each of the prognostic factors ac-
cording to the serum HBV status. Abnormal preoperative
serum CA19-9 (≥ 200U/L) was present in 43.4% patients
with chronic HBV and in 69.6% patients without HBV in-
fection (P = 0.047). Elevated ALP levels were present in
29.7% of patients with HBV infection and in 87% ofFigure 6 Overall survival rate of in 81 ICC patients after surgery
according to the lymph node metastasis or not from the
Kaplan-Meier method.
Figure 7 Overall survival rate of in 81 ICC patients after surgery
according to the operation pattern from the Kaplan-Meier method.
Figure 9 Overall survival rate of in 81 ICC patients after surgery
according to with diabetes or not from the Kaplan-Meier method.
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node metastases were present in 73.2% of patients without
HBV infection and in 46.0% of those with chronic HBV in-
fection (P = 0.001).
The differences in the distribution of these factors in
patients without HBV infection and in those who were
anti-HBs positive did not reach statistical significance al-
though numerical differences were apparent (Table 3).Figure 8 Overall survival rate of in 81 ICC patients after surgery
according to the intrahepatic metastasis or not from the
Kaplan-Meier method.Discussion
The prognosis of ICC remains poor and surgery offers
the only chance of a clinical cure [2]. Although many
traials have reported that cytokine-induced killer (CIK)
cell therapy is safety and effective for hepatocellular car-
cinoma [10], its use in ICC requires further study.
The overall 1- and 3-year survival rate for our series of
81 patients (51% and 20%, respectively) was lower than
that reported by other recent studies [5,6,11]. The reasons
for poor survival in our study were related to the fact that
approximately 26.0% of patients were not well enough to
undergo radical surgery. In addition, 61.7% presented with
lymphatic metastasis, 38.3% had intrahepatic metastasis
and between 35.8% and 71.6% patients had abnormal liver
function at the time of diagnosis.
We showed that HBV infection or vaccine prior to sur-
gery were favorable prognostic factors for survival after re-
section. Patients with occult HBV infection represented by
HBsAg + or anti-HBc + (n = 37) and those who had under-
gone vaccination (n = 21) had a better prognosis than pa-
tients without HBV infection or injection prior to surgery
(n = 23). Multivariate analysis indicated that chronic HBV
infection and anti-HBs positivity both acted as favorable
prognostic factors for overall survival.
Previous studies have investigated the association be-
tween chronic HBV infection and ICC [3,4]. However,
the true impact of HBV on survival of patients with ICC
remains unclear [5,6]. It has been proposed that some of
the mechanisms which underlie ICC related to HBV in-
fection might be similar to those responsible for hepato-
cellular cancer (HCC) which accounts for the shared
clinical features of ICC and HCC [12]. It has been specu-
lated that ICC might originate from a hepatic precursor
cell with a hidden multi-differentiation potential, that can
Table 2 Multivariate analysis of overall survival following resection for ICC (n = 81)
Variate B SE Wald df P Exp(B) 95%CI
Chronic HBV infection −0.539 0.263 4.193 1 0.041 0.583 0.384-0.977
The anti-HBs positive −0.680 0.274 3,256 1 0.050 0.650 0.423-0.994
Lymphatic metastasis 0.841 0.262 10.276 1 0.001 2.320 1.387-3.880
IHDS* −0.749 0.349 4.597 1 0.032 0.473 0.239-0.938
Adjuvant chemotherapy −1.481 0.337 19.294 1 0.000 0.227 0.117-0.440
*IHDS intrahepatic duct stone, TBIL Total bilirubin, ALT Alanine aminotransferase, ALP Alkaline phosphatase, GGT gamma-glutamyl transpeptidase, CA19-9
Carbohydrate antigen 19–9.
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hepatocytes or biliary cells [13]. It is also possible that
fragments of HBV gene may integrate into the host gen-
ome, resulting in cellular transformation and recruitment
of hepatocytes or cholangiocytes with oncogenic potential.
Another possibility is that innate or acquired immune re-
sponses activated by current or recent HBV infection,
might enhance antitumor activity against ICC. ICC associ-
ated with HBV infection, may activate immunologicTable 3 Stratification of prognostic factors by HBV status
Clinical factor Chronic hepatitis P value
Total 37
Age 0.051
≤ 60 y 24 (67.2%)
> 60 y 13 (32.8%)
CA19-9 0.047
≤ 200 U/ml 21 (56.8%)
> 200 U/ml 16 (43.2%)
TIBL 0.051
≤ 20 μmol/L 24 (64.9%)
> 20 μmol/L 13 (35.1%)
GGT 0.496
≤ 64 U/L 11 (29.7%)
> 64 U/L 26 (70.3%)
ALP 0.001
≤ 119 U/L 16 (43.2%)










Adjuvant chemotherapy 8 (21.6%)memory arising from previous HBV infection and thereby
strengthen antitumor immunity [14].
Vaccination is a protective strategy against HBV infec-
tion and the resulting immune responses may explain
why prognosis was improved in patients who had been
vaccinated. However, the exact mechanisms involved re-
quire further study.
The prognosis of ICC was associated with the pres-
ence or absence of HBV infection suggesting that theAll makers negative P value The anti-HBs positive
23 21
0.690
9 (39.1%) 7 (29.2%)
14 (60.9%) 14 (70.8%)
0.622
7 (30.4%) 5 (23.8%)
16 (69.6%) 16 (76.2%)
0.131
9 (39.1%) 13 (61.9%)
14 (60.9%) 8 (38.1%)
0.870
5 (21.7%) 5 (23.8%)
18 (78.3%) 16 (76.2%)
0.202
3 (13.0%) 6 (28.6%)
20 (87.0%) 15 (71.4%)
0.862
6 (26.8%) 5 (23.8%)
17 (73.2%) 16 (76.2%)
0.717
13 (56.5%) 13 (61.9%)
10 (43.5%) 8 (38.1%)
0.820
15 (65.2%) 13 (61.9%)
8 (34.8%) 8 (38.1%)
5 (21.7%) 5 (23.8%)
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ent in these subgroups of patients. Based on this find-
ing, patients with HBV infection may be sensitive to
antiviral or immunological therapy, which may contrib-
ute to the control of the disease.
The use of adjuvant chemotherapy and radiation in ICC
remains controversial [15,16]. Most previous studies of ad-
juvant chemotherapy in ICC are uncontrolled, with small
sample sizes and include patients with gallbladder and pan-
creatic cancer making it difficult to draw clinically meaning-
ful conclusion regarding efficacy. In previous studies, 5-FU
based chemotherapy resulted in response rates of 8%-40%,
and a median survival of 2 to 12 months. Gemcitabine-
based chemotherapy is associated with response rates ran-
ging from 8% to 60% and median survival times ranging
from 6.5 to 16 months [9]. In present study, multivariate
analysis identified adjuvant chemotherapy was an independ-
ent prognostic factor which was associated with an im-
proved median survival of 15 months. This finding suggests
that high risk patients with ICC should receive adjuvant
chemotherapy.
In our study 18 patients received adjuvant chemother-
apy including 12 who underwent transcatheter hepatic
arterial chemoembolization (TACE) and six patients who
received systemic venous antineoplastic therapy. Chemo-
therapy included 5-FU, cisplatin, gemcitabine, doxorubicine
and oxaliplatin. The impact of individual chemotherapy
regimens on prognosis and survival in patients with ICC re-
quires further study in larger populations of patients.
High preoperative CA19-9 levels (> 37 U/ml) have been
shown to influence overall survival of ICC patients after
hepatic resection [17]. Serum CA19-9 has been shown to
be associated to tumor burden [18] and levels > 1000 U/ml
has been shown to be a negative prognostic factor for sur-
vival [19]. In our study, the median survival (12 months)
among patients with preoperative CA19-9 level < 200 U/
ml was far longer than that among patients with CA19-9
levels > 200 U/ml (8 months).
It has also been reported that high CA19-9 levels are sig-
nificantly correlated with important histopathologic factors
such as major vessel, bile duct, and perineural invasion.
These findings indicate that high preoperative CA19-9
levels may predictof histopathologic invasiveness of ICC as
well as poor survival [20].
Lymph node status has been shown to be of prognos-
tic significance among patients without distant metasta-
ses [4,5]. In a previous study 3- and 5-year survival rates
were shown to be 40% and 25% respectively for patients
with N0M0 disease compared to 21% and 4% respect-
ively for those with N1M0 disease [21]. In our study,
survival was compromised by the presence of lymph node
metastasis as demonstrated by both univariate and multi-
variate analysis. In accordance with our findings lymphatic
invasion has been shown to be an independent prognosticfactor for survival, and a more important predictor for
outcomes of ICC than lymph node metastasis [20].
Hepatolithiasis is a common disease in China, and 5%
to 10% of cases of this condition are known to be associated
with cholangiocarcinoma [22]. The clinicopathologic fea-
tures of hepatolithiasis and hepatobiliary cancer (IHHCC)
are similar, and the overall survival associated with IHHCC
is poor [23]. In our study we found that the presence of
intrahepatic duct stones was associated with improved
postoperative survival. This observation was contrary to
previous findings [5,24] indicating that further research is
needed to ascertain the underlying mechanism of action.
In our study, median survival was longer in patients
undergoing radical resection (12 months) than in those
receiving palliative resection (5 months). However, both
survival times were lower than those previously reported
(36 and 10 months, respectively) [16]. This may be re-
lated to the fact that only 60 (84.5%) of the 81 patients
in the study received radical tumor resection.
In common with other studies we found that intra-
hepatic metastasis was a poor prognostic factor for sur-
vival [5,11,16]. Diabetes has also been reported to be a
risk factor for the development of ICC [25]. In our study
the relationship diabetes and the prognosis of ICC was
unclear. However, we did demonstrate that ICC patients
with diabetes had a very short survival time.
Prospective validation of our results based on a larger
multicenter population is required before our findings can
be applied to clinical practice. However, this initial analysis
suggests that current or previous HBV infection or vaccin-
ation may be associated with significantly better prognosis
than in patients without HBV infection. Our findings also
highlight the need to improve early diagnostic accuracy in
order to allow radical tumor resection in as many patients
as possible. Adjuvant chemotherapy appears to prolong
survival for patients unable to tolerate radical resection.
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